D-0122-2020 Class II Ongoing

Recalled by Torrent Pharma Inc. — Basking Ridge, NJ

FDA drug recall D-0122-2020 was initiated by Torrent Pharma Inc. on Sep 19, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million. The recall status is ongoing. Affected quantity: 39,432 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 9, 2019
Initiation Date
Sep 19, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
39,432 bottles

Product description

Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for: Torrent Pharma Inc., Basking Ridge, NJ 07920. NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10

Reason for recall

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Distribution pattern

Nationwide USA and Puerto Rico

Code information

Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0122-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0122-2020. Report a data issue: hello@regdatalab.com.